Since the discovery of insulin in 1921, we have seen a constant stream of innovative insulin formulations designed to more closely mimic physiological insulin secretion in people with type 1 diabetes and insulin-requiring type 2 diabetes. This article briefly reviews the development of inhaled insulin over the past 30 years.
SkylerJS, CefaluWT, KouridesIA, et al.Efficacy of inhaled human insulin in type 1 diabetes mellitus: A randomised proof-of-concept study. Lancet, 2001; 357(9253):331–335.
7.
CefaluWT, SkylerJS, KouridesIA, et al.; Inhaled Insulin Study Group. Inhaled human insulin treatment of patients with type 2 diabetes mellitus. Ann Intern Med, 2001; 134(3):203–207.
8.
HarperNJ, GrayS, de GrootJ, et al.The design and performance of the Exubera® pulmonary insulin delivery system. Diabetes Technol Ther, 2007; 9(,Suppl 1):S16–S27.
9.
CefaluWT, WangZQ. Clinical research observations with use of Exubera® in patients with type 1 and type 2 diabetes. Diabetes Technol Ther, 2007; 9(Suppl 1):S28–S40.
10.
MuchmoreDB, SilvermanB, de la PeñaA, TobianJ. The AIR® inhaled insulin system: System components and pharmacokinetic/glucodynamic data. Diabetes Technol Ther, 2007; 9(,Suppl 1):S41–S47.
11.
EllisSL, GemperlineKA, GargS. Review of phase 2 studies utilizing the AIR® particle technology in the delivery of human insulin inhalation powder versus subcutaneous regular or lispro insulin in subjects with type 1 or type 2 diabetes. Diabetes Technol Ther, 2007; 9,(Suppl 1):S48–S56.
FinkJB, MolloyL, PattonJS, et al.Good things in small packages: An innovative delivery approach for inhaled insulin. Pharm Res, 2017; 34(12):2568–2578.
14.
HeinemannL, BaughmanR, BossA, HompeschM. Pharmacokinetic and pharmacodynamic properties of a novel inhaled insulin. J Diabetes Sci Technol, 2017; 11(1):148–156.
